Ipilimumab-induced Immune-related Renal Failure - A Case Report

被引：0

作者：

Forde, Patrick M. ^{[1
]}

Rock, Kathy ^{[2
]}

Wilson, Graham ^{[3
]}

O'Byrne, Kenneth J. ^{[2
]}

机构：

[1] Johns Hopkins Univ Hosp, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD 21231 USA

[2] St James Hosp, Dept Med Oncol, Dublin 8, Ireland

[3] St James Hosp, Dept Radiol, Dublin 8, Ireland

来源：

ANTICANCER RESEARCH | 2012年 / 32卷 / 10期

关键词：

Ipilimumab; renal failure; melanoma metastasis;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Ipilimumab is a fully human monoclonal antibody targeting cytotoxic T-lymphocyte antigen-4 and has become the first immune checkpoint inhibitor to enter clinical practice, being recently approved for the treatment of metastatic melanoma. Immune toxicity due to ipilimumab causing colitis, hepatitis, dermatitis and hypophysitis is well-described. We report on a case of acute renal failure resolving rapidly with high-dose corticosteroid treatment highlighting the importance of vigilance for rarer immune-related toxicities as clinical experience with ipilhnumab grows.

引用

页码：4607 / 4608

页数：2

共 4 条

[1] Chin K, 2008, ANN ONCOL S8, V19, pvii239
[2] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. Stephen
O'Day, Steven J.
McDermott, David F.
Weber, Robert W.
Sosman, Jeffrey A.
Haanen, John B.
Gonzalez, Rene
Robert, Caroline
Schadendorf, Dirk
Hassel, Jessica C.
Akerley, Wallace
van den Eertwegh, Alfons J. M.
Lutzky, Jose
Lorigan, Paul
Vaubel, Julia M.
Linette, Gerald P.
Hogg, David
Ottensmeier, Christian H.
Lebbe, Celeste
Peschel, Christian
Quirt, Ian
Clark, Joseph I.
Wolchok, Jedd D.
Weber, Jeffrey S.
Tian, Jason
Yellin, Michael J.
Nichol, Geoffrey M.
Hoos, Axel
Urba, Walter J.
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) : 711 - 723
[3] Lebbe C, PERSP MEL 12 2008 M
[4] Principles and use of anti-CTLA4 antibody in human cancer immunotherapy
Peggs, KS
Quezada, SA
Korman, AJ
Allison, JP
[J]. CURRENT OPINION IN IMMUNOLOGY, 2006, 18 (02) : 206 - 213

← 1 →